The Latest in Lung Cancer Treatment and Research

0
Geoffrey Oxnard, MD, and Cloud Paweletz, PhD

Geoffrey Oxnard, MD, and Cloud Paweletz, PhD

Over the last decade, treatment options for lung cancer patients have evolved drastically. Even in just the last few months, promising research has led to new, approved therapies, and researchers anticipate more advances are on the way.

“Drugs are emerging at a rapid pace now,” says Geoffrey Oxnard, MD, of Dana-Farber’s Lowe Center for Thoracic Oncology. “There is a lot of optimism in lung cancer, a lot of options for patients and excitement about new things that are coming.”

Oxnard recently discussed some of these emerging therapies during a live video webchat on the latest lung cancer treatment and research, including new developments in immunotherapy and targeted therapy.

Learn more about these new treatments by watching a recording of the webchat below:

    Make An Appointment

    For adults: 877-960-1562

    Quick access: Appointments as soon as the next day for new adult patients

    For children: 888-733-4662

    All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

    Latest Tweets

    Dana-Farber @danafarber
    Stop by booth #132 to learn more about our cellular therapy and stem cell transplant programs! #BMTTandem18 #ASBMT https://t.co/6YrZN5OsXW
    Dana-Farber @danafarber
    RT @SusanDFCI: Researchers @DanaFarber, led by Irene Ghobrial, MD, are engaged in a study that may eventually help doctors identify individ…
    Dana-Farber @danafarber
    There’s a lot of information on the Internet about cancer and unfortunately, that includes fiction as well as fact.… https://t.co/gOZjLxA1cH

    Republish our posts on your blog

    Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.